A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests - Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris - can help doctors make better decisions ...

—This recent analysis found that, despite similar clinical outcomes, genomic differences were observed in mCRPC differences by race, highlighting the importance of racial diversity in future genomic ...

Credit: Getty Images Investigators explore the biomarker potential of circulating tumor DNA and tumor suppressor gene status. Elevated circulating tumor DNA fraction and tumor suppressor gene loss are ...

Prostate cancer disproportionately affects men of African ancestry, yet the molecular mechanisms underlying these disparities remain poorly defined. Genomic studies have begun to reveal ...

Therapeutic advances have improved cancer outcomes, but early-stage detection remains the single most important determinant of favorable prognoses across many cancer types. Cancer genomics has yielded ...

It is not unusual for advanced prostate cancer to become resistant to treatment. Of these resistant cases, some progress to a specific form of the disease, which is particularly aggressive and deadly.

Researchers have identified the genetic risk factors that contribute to prostate cancer in a diverse group of African men. Although research and treatment are scant, this first large-scale African ...

Among men worldwide, prostate cancer is the second most common cancer and the fifth leading cause of cancer deaths. As the world's population ages, the number of prostate cancer patients is expected ...

Intensification of androgen deprivation therapy (ADT) in metastatic hormone sensitive prostate cancer (mHSPC): Patterns of use and impact on outcomes from a large academic medical center. Evaluating ...

Daniel W. Lin, MD, reviews new guidance on using MRI, biomarkers, and more, to improve the detection of prostate cancer.